Seeking Alpha

Lineage Cell Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Positive RG6501 (OpRegen ®) Phase 1/2a Clinical Study 36 Month Results Featured at Clinical Trials at the Summit 2025 Entered Collaboration with William Demant Invest to Develop ReSonance™ (ANP1) for ...
Hosted on MSN

Lineage Cell Therapeutics outlines manufacturing milestone and anticipates OpRegen 36-month data update while advancing OPC1 clinical plans

CEO Brian Culley highlighted the progress of OpRegen, noting its differentiation from current anti-complement therapies for dry AMD. He emphasized, “OpRegen has shown evidence of both anatomical and ...
Hosted on MSN

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2025 Earnings Call Transcript

Lineage Cell Therapeutics, Inc. (AMEX:LCTX) Q2 2025 Earnings Call Transcript August 12, 2025 Lineage Cell Therapeutics, Inc. misses on earnings expectations. Reported EPS is $-0.13 EPS, expectations ...
Seeking Alpha

Lineage Cell Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (LCTX) (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf”, cell ...
Nasdaq

Lineage Cell Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Russo Partners – Media Relations Nic Johnson or David Schull ([email protected]) ([email protected]) (212) 845-4242 Source: Lineage Cell Therapeutics, Inc. The views and ...